• Explore /
  • Poster
  • / Final results of a phase 1b/2 study of tivozanib in combination with durvalumab in patients with advanced hepatocellular carcinoma in both previously untreated patients and patients progressing on atezolizumab and bevacizumab.

Final results of a phase 1b/2 study of tivozanib in combination with durvalumab in patients with advanced hepatocellular carcinoma in both previously untreated patients and patients progressing on atezolizumab and bevacizumab.

Abstract Poster

Authors

null

Daneng Li

City of Hope National Comprehensive Cancer Center, Duarte, CA;

Daneng Li , Farshid Dayyani , Devalingam Mahalingam , Julie Haewon Rowe , Thomas Adam Abrams , Vijay Kasturi , Renuka V. Iyer

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2023 ASCO Gastrointestinal Cancers Symposium

Session Type

Poster Session

Session Title

Poster Session B: Cancers of the Pancreas, Small Bowel, and Hepatobiliary Tract

Track

Pancreatic Cancer,Hepatobiliary Cancer,Neuroendocrine/Carcinoid,Small Bowel Cancer

Sub Track

Therapeutics

Clinical Trial Registration Number

NCT03970616

Citation

J Clin Oncol 41, 2023 (suppl 4; abstr 585)

DOI

10.1200/JCO.2023.41.4_suppl.585

Abstract #

585

Poster Bd #

E17

Abstract Disclosures

Similar Posters

First Author: Renuka V. Iyer

First Author: Takeshi Terashima

First Author: Farshid Dayyani

First Author: Kazuomi Ueshima